These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 33869816)

  • 1. Design, synthesis and evaluation of novel enzalutamide analogues as potential anticancer agents.
    Bhole RP; Chikhale RV; Wavhale RD; Asmary FA; Almutairi TM; Alhajri HM; Bonde CG
    Heliyon; 2021 Mar; 7(3):e06227. PubMed ID: 33869816
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A novel androgen receptor antagonist JJ-450 inhibits enzalutamide-resistant mutant AR
    Wu Z; Wang K; Yang Z; Pascal LE; Nelson JB; Takubo K; Wipf P; Wang Z
    Prostate; 2020 Mar; 80(4):319-328. PubMed ID: 31868960
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Design, Synthesis and Evaluation of Novel Substituted (5-methyl-1H-pyrazol-3-yl)- 1,3,4-oxadiazole as Potent Androgen Receptor Antagonist.
    Andavar S; Vaithilingam M; Selvaraj D; Kumaran AA; Devanathan K
    Anticancer Agents Med Chem; 2020; 20(1):84-93. PubMed ID: 31755396
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hybrid Enzalutamide Derivatives with Histone Deacetylase Inhibitor Activity Decrease Heat Shock Protein 90 and Androgen Receptor Levels and Inhibit Viability in Enzalutamide-Resistant C4-2 Prostate Cancer Cells.
    Rosati R; Chen B; Patki M; McFall T; Ou S; Heath E; Ratnam M; Qin Z
    Mol Pharmacol; 2016 Sep; 90(3):225-37. PubMed ID: 27382012
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Molecular Dynamics Studies on the Enzalutamide Resistance Mechanisms Induced by Androgen Receptor Mutations.
    Liu H; Wang L; Tian J; Li J; Liu H
    J Cell Biochem; 2017 Sep; 118(9):2792-2801. PubMed ID: 28181296
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The androgen receptor antagonist enzalutamide induces apoptosis, dysregulates the heat shock protein system, and diminishes the androgen receptor and estrogen receptor β1 expression in prostate cancer cells.
    Abazid A; Martin B; Choinowski A; McNeill RV; Brandenburg LO; Ziegler P; Zimmermann U; Burchardt M; Erb H; Stope MB
    J Cell Biochem; 2019 Oct; 120(10):16711-16722. PubMed ID: 31297844
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Molecular characterization of enzalutamide-treated bone metastatic castration-resistant prostate cancer.
    Efstathiou E; Titus M; Wen S; Hoang A; Karlou M; Ashe R; Tu SM; Aparicio A; Troncoso P; Mohler J; Logothetis CJ
    Eur Urol; 2015 Jan; 67(1):53-60. PubMed ID: 24882673
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Synthesis, Anticancer Activity on Prostate Cancer Cell Lines and Molecular Modeling Studies of Flurbiprofen-Thioether Derivatives as Potential Target of MetAP (Type II).
    Yılmaz Ö; Bayer B; Bekçi H; Uba AI; Cumaoğlu A; Yelekçi K; Küçükgüzel ŞG
    Med Chem; 2020; 16(6):735-749. PubMed ID: 31203805
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Discovery and biological evaluation of novel androgen receptor antagonist for castration-resistant prostate cancer.
    Yu J; Zhang L; Yan G; Zhou P; Cao C; Zhou F; Li X; Chen Y
    Eur J Med Chem; 2019 Jun; 171():265-281. PubMed ID: 30925341
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A clinically relevant androgen receptor mutation confers resistance to second-generation antiandrogens enzalutamide and ARN-509.
    Joseph JD; Lu N; Qian J; Sensintaffar J; Shao G; Brigham D; Moon M; Maneval EC; Chen I; Darimont B; Hager JH
    Cancer Discov; 2013 Sep; 3(9):1020-9. PubMed ID: 23779130
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combined N-terminal androgen receptor and autophagy inhibition increases the antitumor effect in enzalutamide sensitive and enzalutamide resistant prostate cancer cells.
    Kranzbühler B; Salemi S; Mortezavi A; Sulser T; Eberli D
    Prostate; 2019 Feb; 79(2):206-214. PubMed ID: 30345525
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Synthesis and evaluation of 7-(3-aminopropyloxy)-substituted flavone analogue as a topoisomerase IIα catalytic inhibitor and its sensitizing effect to enzalutamide in castration-resistant prostate cancer cells.
    Jeon KH; Park S; Shin JH; Jung AR; Hwang SY; Seo SH; Jo H; Na Y; Kwon Y
    Eur J Med Chem; 2023 Jan; 246():114999. PubMed ID: 36493620
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Moving Towards Precision Urologic Oncology: Targeting Enzalutamide-resistant Prostate Cancer and Mutated Forms of the Androgen Receptor Using the Novel Inhibitor Darolutamide (ODM-201).
    Borgmann H; Lallous N; Ozistanbullu D; Beraldi E; Paul N; Dalal K; Fazli L; Haferkamp A; Lejeune P; Cherkasov A; Gleave ME
    Eur Urol; 2018 Jan; 73(1):4-8. PubMed ID: 28851578
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Design and synthesis of novel bicalutamide and enzalutamide derivatives as antiproliferative agents for the treatment of prostate cancer.
    Bassetto M; Ferla S; Pertusati F; Kandil S; Westwell AD; Brancale A; McGuigan C
    Eur J Med Chem; 2016 Aug; 118():230-43. PubMed ID: 27131065
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Discovery of deshydroxy bicalutamide derivatives as androgen receptor antagonists.
    Kandil S; Lee KY; Davies L; Rizzo SA; Dart DA; Westwell AD
    Eur J Med Chem; 2019 Apr; 167():49-60. PubMed ID: 30743097
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Syringaresinol as a novel androgen receptor antagonist against wild and mutant androgen receptors for the treatment of castration-resistant prostate cancer: molecular docking,
    Selvaraj D; Muthu S; Kotha S; Siddamsetty RS; Andavar S; Jayaraman S
    J Biomol Struct Dyn; 2021 Feb; 39(2):621-634. PubMed ID: 31928160
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An F876L mutation in androgen receptor confers genetic and phenotypic resistance to MDV3100 (enzalutamide).
    Korpal M; Korn JM; Gao X; Rakiec DP; Ruddy DA; Doshi S; Yuan J; Kovats SG; Kim S; Cooke VG; Monahan JE; Stegmeier F; Roberts TM; Sellers WR; Zhou W; Zhu P
    Cancer Discov; 2013 Sep; 3(9):1030-43. PubMed ID: 23842682
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibition of protein kinase C/Twist1 signaling augments anticancer effects of androgen deprivation and enzalutamide in prostate cancer.
    Shiota M; Yokomizo A; Takeuchi A; Imada K; Kashiwagi E; Song Y; Inokuchi J; Tatsugami K; Uchiumi T; Naito S
    Clin Cancer Res; 2014 Feb; 20(4):951-61. PubMed ID: 24352647
    [TBL] [Abstract][Full Text] [Related]  

  • 19. IAP Antagonists Enhance Apoptotic Response to Enzalutamide in Castration-Resistant Prostate Cancer Cells via Autocrine TNF-α Signaling.
    Pilling AB; Hwang O; Boudreault A; Laurent A; Hwang C
    Prostate; 2017 Jun; 77(8):866-877. PubMed ID: 28240376
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Structural and molecular insights into the mechanism of resistance to enzalutamide by the clinical mutants in androgen receptor (AR) in castration-resistant prostate cancer (CRPC) patients.
    Khan A; Mao Y; Tahreem S; Wei DQ; Wang Y
    Int J Biol Macromol; 2022 Oct; 218():856-865. PubMed ID: 35905763
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.